QNRX
FDA Grants QUOIN PHARMACEUTICALS Second Rare Pediatric Tag for QRX003
Quoin's lead asset QRX003 receives Rare Pediatric Disease Designation for Peeling Skin Syndrome, opening the door to a second Priority Review Voucher.
Regulatory
ABAT
AMERICAN BATTERY TECHNOLOGY Clears BLM Hurdle for Tonopah Flats Lithium
The Bureau of Land Management accepted the mine and refinery Plan of Operations for ABTC's Nevada lithium project, moving it into environmental review.
GFS
GLOBALFOUNDRIES to Issue 9.9M Shares to U.S. Commerce Department
GlobalFoundries will hand the Commerce Department nearly 9.91 million ordinary shares at $37.85 apiece, a stake worth roughly $375 million.
DFTX
FDA Grants DEFINIUM Second Breakthrough Therapy Tag for LSD Tablet
Definium's DT120 gets Breakthrough Therapy designation in major depressive disorder after a Phase 3 win, adding to an earlier tag in generalized anxiety.
AZN
FDA Approves ASTRAZENECA Breast Cancer Drug Etcamah for First-Line Use
Accelerated US approval of camizestrant with a CDK4/6 inhibitor rests on SERENA-6, which cut the risk of progression or death by 56%.
QBTS
D-WAVE Signs $100M CHIPS Act Award With Commerce Department
D-Wave Quantum has entered a $100 million Other Transaction Agreement with the U.S. Department of Commerce to prototype scalable superconducting quantum components.
POMRY
POMMERY Auditors Flag Material Going-Concern Doubt in 2025 Filing
The Champagne group's 2025 registration document carries an auditor paragraph on material uncertainty over its ability to continue as a going concern.
Regulatory
PHARMA EQUITY GROUP Faces Court Challenge to EUR 10.5M Arbitral Award
Interpatium has asked a Danish district court to set aside the June 2026 arbitration ruling that ordered it to pay Pharma Equity Group EUR 10.5 million.
GURE
GULF RESOURCES Files 8-K on Nasdaq Listing Deficiency
The Shandong-based chemicals producer disclosed an Item 3.01 notice covering delisting or failure to satisfy a continued listing rule.
QNCX
QUINCE THERAPEUTICS Files 8-K Flagging Listing Rule Issue
The biotech filed an Item 3.01 disclosure with the SEC covering a delisting notice or failure to meet a continued listing standard, dated August 31, 2026.
SNTI
SENTI BIOSCIENCES Files Amended Terms for Senior Secured Convertible Notes
An 8-K discloses a revised form of senior secured convertible note maturing November 23, 2026, repayable in cash at 200% of outstanding principal.
DPU
TOP KINGWIN Holders Approve 1-for-50 Reverse Split and Nexpu Name Change
Shareholders backed a 200x supervoting Class B structure, a jump in authorized capital to $625 million and a share consolidation effective December 17, 2026.